Basit öğe kaydını göster

dc.contributor.authorHavrdova, Eva
dc.contributor.authorLimmroth, Volker
dc.contributor.authorPolman, Chris H.
dc.contributor.authorKappos, Ludwig
dc.contributor.authorSchmierer, Klaus
dc.contributor.authorYousry, Tarek A.
dc.contributor.authorYang, Minhua
dc.contributor.authorERAKSOY, Mefküre
dc.contributor.authorMeluzinova, Eva
dc.contributor.authorRektor, Ivan
dc.contributor.authorDawson, Katherine T.
dc.contributor.authorSandrock, Alfred W.
dc.contributor.authorO'Neill, Gilmore N.
dc.contributor.authorGold, Ralf
dc.contributor.authorMiller, David H.
dc.contributor.authorMacManus, David G.
dc.date.accessioned2022-02-18T10:37:03Z
dc.date.available2022-02-18T10:37:03Z
dc.date.issued2008
dc.identifier.citationKappos L., Gold R., Miller D. H. , MacManus D. G. , Havrdova E., Limmroth V., Polman C. H. , Schmierer K., Yousry T. A. , Yang M., et al., "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study", LANCET, cilt.372, sa.9648, ss.1463-1472, 2008
dc.identifier.issn0140-6736
dc.identifier.othervv_1032021
dc.identifier.otherav_ad59f8da-e9e8-4897-9acc-3d64c056bc9b
dc.identifier.urihttp://hdl.handle.net/20.500.12627/179589
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(08)61619-0
dc.description.abstractBackground Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis.
dc.language.isoeng
dc.subjectAssessment and Diagnosis
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.titleEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
dc.typeMakale
dc.relation.journalLANCET
dc.contributor.departmentUniversitaet Basel (University Of Basel) , ,
dc.identifier.volume372
dc.identifier.issue9648
dc.identifier.startpage1463
dc.identifier.endpage1472
dc.contributor.firstauthorID3376138


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster